Identifying the frequency and prognostic relevance of the expression of the immunosuppressive ligand, Programmed Death-Ligand 1, in glioblastoma patient tissue (Nduom et al., Neuro-Oncology, 2016; Pratt et al. Neurosurgery, 2018)
The development of a clinical trial to use cerebral microdialysis to determine the response to me-adjuvant immune checkpoint inhibition in recurrent glioblastoma patients (Lynes et al., Neurosurgery, 2018; NCT03493932)
Pre-clinical work to discover better combinations of immune modulatory treatments to improve effector T-cell infiltration for the treatment of glioblastoma
Discovery of long non-coding RNAs in glioblastoma patient immune cells that could be targeted to improve immune therapy in glioblastoma patients.